La colchicina alivia la aterosclerosis combinada con la diabetes mellitus al dirigirse a PIM2 y regular la vía de señalización NF-κB.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.La colchicina trata eficazmente la aterosclerosis en ratones diabéticos reduciendo la inflamación y dirigiéndose a la proteína PIM2. Este medicamento antiinflamatorio es prometedor para el tratamiento de la enfermedad coronaria (CHD) en pacientes diabéticos.
Área De La Ciencia
- Farmacología
- Medicina cardiovascular
- Inmunología
Sus Antecedentes
- La prevalencia de la enfermedad coronaria (CHD) está aumentando en todo el mundo, exacerbada por la diabetes mellitus (DM).
- Las terapias existentes para la aterosclerosis no abordan completamente las exacerbaciones relacionadas con la DM.
- La colchicina, un agente antiinflamatorio, muestra potencial para la enfermedad coronaria, pero requiere más investigación.
Objetivo Del Estudio
- Investigar los efectos y mecanismos de la colchicina en el tratamiento de la aterosclerosis con DM.
- Validar los hallazgos mediante la farmacología en red y modelos experimentales.
Principales Métodos
- Objetivos de enfermedades y fármacos identificados mediante bases de datos bioinformáticas (GeneCard, OMIM, DisGeNET, DGIDB, Swiss Target Prediction).
- Realizó el análisis de enriquecimiento de la Ontología Genética (GO) y la Enciclopedia de Kyoto de Genes y Genomas (KEGG).
- Se utilizó la secuenciación del transcriptoma, el acoplamiento molecular, la dinámica molecular, la resonancia plasmónica de superficie (SPR) y un modelo de ratón de aterosclerosis diabética inducida por STZ (APOE-/-).
Principales Resultados
- Se identificaron 140 objetivos potenciales, involucrados principalmente en las vías inflamatorias e inmunes (MAPK, Jak-STAT, NF-κB).
- Se descubrieron cuatro objetivos principales de macrófagos (PIM2, SIGLEC1, ANPEP, MAPK10) con una fuerte unión a la colchicina, especialmente a PIM2.
- La colchicina redujo el área de la placa aterosclerótica, la acumulación de macrófagos y los marcadores inflamatorios (IL-1β, IL-6) in vivo e in vitro, validando el PIM2 como objetivo clave.
Conclusiones
- La colchicina muestra potencial como tratamiento antiinflamatorio para la aterosclerosis en pacientes diabéticos.
- El mecanismo implica apuntar a PIM2 para modular la función de los macrófagos y suprimir las vías inflamatorias.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...